Levetiracetam Kern Pharma

Levetiracetam, the active ingredient in Levetiracetam Kern Pharma, is an antiepileptic presented as an injection for intravenous use. It is indicated for the treatment of partial, generalized tonic‑clonic and myoclonic seizures in patients requiring rapid control of seizure activity. GNH USA supplies Levetiracetam Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levetiracetam is an antiepileptic agent used to control various seizure types. - Partial seizures: reduces the frequency of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. - Myoclonic seizures: diminishes sudden muscle jerks associated with myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: sensation of light‑headedness or imbalance. - Headache: mild to moderate cranial pain. - Irritability: increased emotional sensitivity or mood changes. - Nausea: upset stomach or urge to vomit. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood disorders: depression, anxiety, or suicidal thoughts. - Hematologic changes: low blood cell counts. - Liver enzyme elevation: signs of hepatic stress. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function: adjust dosing in patients with impaired clearance. - Pregnancy: safety data are limited; weigh benefits against potential risks. - Concomitant CNS depressants: monitor for additive sedation. - History of psychiatric illness: observe for mood changes. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: can lower levetiracetam exposure. - Phenytoin: may decrease levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: increased central nervous system depression. - Sedative antihistamines: enhanced drowsiness. - Other antiepileptics (e.g., valproate): monitor seizure control and side‑effect profile.